Center-Authored Papers

Filters: Author is Tangen, Catherine  [Clear All Filters]
2017
Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML.  2017.  Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.. Nutrients. 9(4) Abstract
2016
Hussain M, Tangen C, Higano C, Vogelzang N, Thompson I.  2016.  Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(3):280-285. Abstract
LeBlanc M, Tangen C.  2016.  Surrogates for Survival or Other End Points in Oncology.. JAMA oncology. 2(2):263-4.
2014
Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ et al..  2014.  Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.. Journal of the National Cancer Institute. Abstract
2013
Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR.  2013.  Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia? American journal of epidemiology. Abstract
2012
LeBlanc M, Tangen C.  2012.  Choosing Phase II Endpoints and Designs: Evaluating the Possibilities.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(8):2130-2. Abstract